The FDA has granted tucatinib a breakthrough therapy designation for use in combination with trastuzumab (Herceptin) and capecitabine (Xeloda) for the treatment of patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including patients with brain metastases, who had prior trastuzumab, pertuzumab (Perjeta), and ado-trastuzumab emtansine (T-DM1; Kadcyla).
Within approximately 1 year, 3 combination regimens featuring immunotherapy agents were approved by the FDA for the frontline treatment of patients with metastatic renal cell carcinoma (RCC), said Robert J. Motzer, MD.
An expert discusses how clinicians choose between PARP inhibitors for patients with ovarian cancer, and what may be coming next in the field.
The FDA has approved a supplemental new drug application for enzalutamide (Xtandi) for the treatment of patients with metastatic castration-sensitive prostate cancer.
Residual cancer burden (RCB) after neoadjuvant chemotherapy has been shown to be an accurate long-term predictor of disease recurrence and survival across all breast cancer subtypes, according to data from a large meta-analysis presented at the 2019 San Antonio Breast Cancer Symposium.
There's a title wave of older adults flooding the healthcare system. Hear from two oncology nurses on how practitioners can be preapred to give high-quality care.
A durvalumab (Imfinzi)-based neoadjuvant regimen induced a pathologic complete response (pCR) rate of 44% in patients with triple-negative breast cancer (TNBC), according to results of a phase I/II study presented in a poster at the 2019 San Antonio Breast Cancer Symposium.
Researchers and clinicians should consider treatment-free survival when analyzing the results of clinical trials, according to one expert.
Real-world clinical practice results for frontline palbociclib (Ibrance) indicate that the positive progression-free survival (PFS) data previously reported with the CDK4/6 inhibitor in the pivotal PALOMA-2 trial would likely translate to an overall survival (OS) benefit in patients with HR-positive/HER2-negative metastatic breast cancer.
An expert discusses recent exciting advances in the treatment landscape of metastatic melanoma.
Trastuzumab deruxtecan had an ORR rate of nearly 61% for patients with advanced HER2-positive breast cancer.
A majority of adult patients with β-thalassemia who require regular red blood cell (RBC) transfusions experienced clinically meaningful and durable transfusion burden reduction associated with luspatercept (Reblozyl) in the phase III BELIEVE trial.
The FDA has approved 2 abbreviated new drug applications (ANDAs) for everolimus (Afinitor) tablets for the treatment of patients numerous malignancies.
CAR T-cell therapy is an emerging targeted therapy that has large potential for patients whose disease is relapsed or refractory.
The combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) elicited a 100% overall response rate (ORR) in patients with relapsed indolent non-Hodgkin lymphoma (NHL) that was refractory to rituximab (Rituxan), according to findings of a single-arm, phase I/II trial presented at the 2019 ASH Annual Meeting.
Steroid use while cytokine release syndrome (CRS) and neurologic toxicities are at grade 1, instead of waiting until grade 3, reduces the rate of CAR T-cell treatment–related CRS and neurologic events.
Resistance to aromatase inhibitors (AIs) is a growing concern in patients with advanced hormone receptor (HR)–positive, HER2-negative breast cancer, said Hope S. Rugo, MD, FASCO, who added that although fulvestrant (Faslodex) has shown some activity in patients who develop ESR1 mutations, more effective treatment options are needed.
While cytoreductive nephrectomy has been a mainstay in kidney cancer treatment, there are factors to consider before using the procedure on patients with the disease.
Glioblastoma is historically difficult to treat, but recent research shows some potential for immunotherapy/vaccine combinations for these patients.
Recent findings showed patients with advanced melanoma had a favorable complete response to nivolumab and ipilimumab due to potential biomarkers in the disease.
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to abatacept (Orencia) to prevent moderate or severe acute graft-versus-host disease (GvHD) in patients who underwent a hematopoietic stem cell transplant and are not related to their donors, according to Bristol-Myers Squibb, the manufacturer of the drug.
The FDA has approved atezolizumab (Tecentriq) in combination with carboplatin and nab-paclitaxel (Abraxane) for the first-line treatment of adult patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) who do not harbor EGFR or ALK molecular aberrations.
New findings show that while nurses need to provide more palliative care to patients, they are not prepared to do so, leading to high levels of moral distress.
The FDA has granted a priority review designation to pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)–unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.
The FDA has granted a priority review designation to a supplemental Biologics License Application (sBLA) for durvalumab (Imfinzi) for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).1
Here are the top 5 Oncology Nursing News® stories for November 2019.
JAK inhibitors have been the standard of care for patients with myelofibrosis, but now patients need novel agents to help.
The FDA has granted a priority review to the agent pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements.
New approvals in the treatment of patients with myeloma has led to the question of what sequencing of drugs will work best for patients.
